Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genelux Corp. ( (GNLX) ) has issued an update.
On December 30, 2025, Genelux Corporation’s Chief Medical Officer, Paul Scigalla, M.D., resigned effective immediately, and on January 2, 2026, the company appointed oncology specialist Jason Litten, M.D., as its new Chief Medical Officer. Litten, a veteran of Chimeric Therapeutics, Artiva Biotherapeutics, Juno Therapeutics, Clovis Oncology and Amgen, brings extensive experience in developing CAR-T, TCR, NK cell therapies and other cancer medicines; his compensation package includes a $475,000 base salary, performance-based bonus eligibility, equity incentives with change-in-control acceleration, and severance protections, underscoring Genelux’s effort to strengthen its clinical leadership and retain key talent during potential corporate transitions.
The most recent analyst rating on (GNLX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.
Spark’s Take on GNLX Stock
According to Spark, TipRanks’ AI Analyst, GNLX is a Underperform.
Genelux Corp.’s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis suggests bearish momentum, further contributing to the low score. The absence of earnings call insights and corporate events means these factors do not influence the score.
To see Spark’s full report on GNLX stock, click here.
More about Genelux Corp.
Genelux Corporation operates in the biopharmaceutical sector, focusing on oncology drug development. The company develops cancer therapeutics and positions itself in the competitive landscape of innovative cancer treatments, leveraging clinical and preclinical expertise in advanced modalities such as cell therapies and targeted oncology medicines.
Average Trading Volume: 223,637
Technical Sentiment Signal: Hold
Current Market Cap: $165.9M
Find detailed analytics on GNLX stock on TipRanks’ Stock Analysis page.